Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to ...

The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Facing steep competition, Novo Nordisk has slashed the price for its weight loss drug Wegovy — temporarily, at least.

ASHLAND A weight loss clinic with multiple locations in Kentucky, including Ashland, is facing accusations of providing patients with non-FDA approved semaglutide — falsely advertising a compounded ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

The 'Ladies First' rapper has partnered with Novo Nordisk to create more awareness around obesity and cardiovascular disease.

(Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.